ClinicalTrials.gg
RecruitingNCT04924322CRETEUpdated Jun 8, 2026

Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies

A Phase 2/3 interventional study of Enoxaparin in Deep Venous Thrombosis, sponsored by Yale University. Recruiting at 22 sites in United States. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Yale University · Phase 2/3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 42 studies testing enoxaparin in Venous Thrombosis — 3 open to participants now, 3 under way, 1 of them phase 3. Enoxaparin · Venous Thrombosis.

Planned enrollment
12th of 42
258 · median 114
Started
2022
the only one that year
Phase 2/3
2 of 42
1 open now
Registered
40th of 42
by date
Lead sponsor
2 of 42
Yale University

Among the 42 studies testing enoxaparin in Venous Thrombosis, this one is the 12th largest by planned enrollment, is the only one that started in 2022, is one of 2 in phase 2/3, and was the 40th registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

3 of the 42 studies testing enoxaparin in Venous Thrombosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About enoxaparin

Enoxaparin: first FDA approval 1993 (LOVENOX (PRESERVATIVE FREE)), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: Up to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing enoxaparin in Venous Thrombosis, or all of them as a file.
02

Study summary

The goal of the CRETE Studies is to investigate the newly identified age-dependent heterogeneity in the efficacy of enoxaparin in reducing the risk of central venous catheter-associated deep venous thrombosis in critically ill children.

Read the detailed description

Pediatric venous thromboembolism (VTE), which is predominantly deep venous thrombosis (DVT), is a top contributor to harm in hospitalized children. Its incidence increased by >300% in the past 2 decades. Critical illness and central venous catheter (CVC) are the most important risk factors for VTE in children. Among critically ill children, the risk of CVC-associated DVT (CADVT) is as high as 54% with 72% of cases in infants \<1-year old. Pharmacologic prophylaxis is the most effective strategy against VTE in adults. However, due to paucity of age-appropriate evidence on its efficacy against CADVT, pharmacologic prophylaxis is uncommon in children. Extrapolation of evidence from adults is not appropriate because the hemostatic system changes significantly with age. The investigators recently completed a Bayesian phase 2b randomized clinical trial. In this trial, the investigators randomized critically ill children to early administration of prophylactic dose of enoxaparin, the most commonly used anticoagulant for prophylaxis, or usual care. Prophylaxis with enoxaparin appeared to reduce the risk of CADVT by half. In post hoc analyses, reduction was limited to older children 1-17 years old. The goal of the CRETE Studies is to investigate this newly identified age-dependent heterogeneity in the efficacy of enoxaparin in reducing the risk of CADVT in critically ill children. To achieve this goal, the investigators aim (1) to confirm the efficacy and safety of early administration of prophylactic dose of enoxaparin in reducing the risk of CADVT in critically ill older children; (2) to determine the efficacy and safety of early administration of therapeutic dose of enoxaparin in reducing the risk of CADVT in critically ill infants; and, (3) to probe the mechanisms that underly the age-dependent heterogeneity in the efficacy of enoxaparin in reducing the risk of CADVT in critically ill children. The investigators will conduct 2 multicenter Bayesian explanatory randomized clinical trials in parallel to address Specific Aims 1 and 2. Depending on age, subjects will be randomized to different doses of enoxaparin vs usual care. Subjects will be systematically assessed for the development of CADVT using ultrasonography and clinically for bleeding. Using plasma obtained from subjects in the 2 trials, the investigators will conduct an exploratory mechanistic nested case-control study to address Specific Aim 3. Biomarkers of selected mechanisms underlying CVC-associated thrombus formation, particularly thrombin generation, will be compared between subjects with and without CADVT. The investigators will use Bayesian methods to improve the efficiency in the conduct and analyses of these studies. The CRETE Studies will provide high-quality age-appropriate evidence that will inform preventive strategies against CADVT and decrease harm in hospitalized children.

03

Conditions studied

  • Deep Venous Thrombosis

Keywords

  • child
  • critical illness
  • venous thromboembolism
  • enoxaparin
  • thrombin generation
  • bleed
04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. >36 weeks corrected gestational to \<17 years old
  2. \<24 hours after insertion of an untunneled CVC
  3. CVC inserted in the internal jugular or femoral vein

Exclusion criteria

Exclusion criteria

  1. Radiologic diagnosis of CADVT in the site of insertion in prior 6 weeks
  2. Currently receiving an antithrombotic agent, e.g., LMWH, UFH, warfarin and aspirin, but not UFH at dose to maintain patency of a vascular catheter
  3. Presence of bleeding, i.e., decreased ≥2 g/dl in 24 hours, required medical or surgical intervention to restore hemostasis, or in the retroperitoneum, pulmonary, intracranial or central nervous system, in the prior 60 days
  4. Surgery in the prior 7 days
  5. Major trauma in the prior 7 days
  6. Presence of coagulopathy, i.e., >2.0, aPTT >50 seconds or count \<50 x 10\^3/mcL
  7. Presence of renal failure, i.e., \<30 mL/min/1.73 m2
  8. Known to heparin or pork products
  9. Laboratory confirmed HIT
  10. Current pregnancy or lactation
  11. Presence of an epidural catheter
  12. Limitation of care
  13. Previous enrollment in the CRETE Studies
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
258 participants (estimated)

Study arms

  • Experimental
    Enoxaparin (Older Children Prophylactic)

    Prophylactic dose of enoxaparin for older children 1-17 years old.

    Drug: Enoxaparin

  • No intervention
    Control (Older Children)

    Usual care without placebo for older children 1-17 years old.

  • Experimental
    Enoxaparin (Infants Therapeutic High Anti-Xa Target)

    Therapeutic dose of enoxaparin for infants \<1 year old with anti-Xa target of \>0.5-1 IU/mL.

    Drug: Enoxaparin

  • Experimental
    Enoxaparin (Infants Therapeutic Low Anti-Xa Target)

    Therapeutic dose of enoxaparin for infants \<1 year old with anti-Xa target of 0.2-0.5 IU/mL.

    Drug: Enoxaparin

  • No intervention
    Control (Infants)

    Usual care without placebo for infants \<1 year old.

Interventions

  • Enoxaparin is a LMWH produced from UFH that exerts its anticoagulant effects by binding to and inducing a conformational change in antithrombin to accelerate the inactivation of factor Xa and thrombin. Age-specified dose of enoxaparin will be administered within 24 hours after insertion of the CVC with the dose subsequently adjusted to pre-specified anti-Xa target.

    Also known as: Lovenox, Clexane

06

What researchers measure

Primary outcomes

  1. Number of children with CADVT

    Thrombus in the central vein where the CVC was inserted that is diagnosed with systematic ultrasonographic surveillance.

    Time frame: Up to removal of CVC (maximum of 28 days)

Secondary outcomes

  1. Number of children with any VTE

    Thrombus in the deep vein of any extremity or PE that is confirmed radiologically

    Time frame: Up to removal of CVC (maximum of 28 days)

  2. Number of children with clinically apparent CADVT

    Any CADVT, except one that is only diagnosed with the systematic ultrasonographic surveillance.

    Time frame: Up to removal of CVC (maximum of 28 days)

  3. Number of children with clinically apparent VTE

    Any VTE, except one that is only diagnosed with the systematic ultrasonographic surveillance.

    Time frame: Up to removal of CVC (maximum of 28 days)

  4. Number of children with clinically relevant bleeding

    Bleeding that is fatal, with drop in hemoglobin by ≥2 g/dl in 24 hours, requires medical or surgical intervention to restore hemostasis, or in the retroperitoneum, pulmonary or central nervous system.

    Time frame: Maximum of 36 hours after the last dose of enoxaparin

  5. Number of children with any bleeding

    Any overt or macroscopic evidence of bleeding.

    Time frame: Maximum of 36 hours after the last dose of enoxaparin

  6. Number of children with heparin-induced thrombocytopenia

    Unexplained drop in platelet count to \<50 x 10\^3/mcL or by 50 percent of baseline platelet count in the ICU within 21 days following exposure to heparin, and with a positive anti-platelet factor 4 antibody.

    Time frame: Maximum of 36 hours after the last dose of enoxaparin

07

Study locations

20 of 22 sites recruiting
08

References and documents

Publications

  • Faustino EVS, Kandil SB, Leroue MK, Sochet AA, Kong M, Cholette JM, Nellis ME, Pinto MG, Chegondi M, Ramirez M, Schreiber H, Kerris EWJ, Glau CL, Kolmar A, Muisyo TM, Sharathkumar A, Polikoff L, Silva CT, Ehrlich L, Navarro OM, Spinella PC, Raffini L, Taylor SN, McPartland T, Shabanova V; Catheter-Related Early Thromboprophylaxis with Enoxaparin (CRETE) Studies Investigators and the Pediatric Critical Care Blood Research Network (BloodNet) of the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI). Protocol for the Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Studies. Pediatr Crit Care Med. 2025 Jan 1;26(1):e95-e105. doi: 10.1097/PCC.0000000000003648. Epub 2024 Nov 20. PubMed 39560771 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2022 (actual). Primary completion is estimated for Apr 2027, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2021
First posted
Jun 11, 2021
StartActual
May 11, 2022
Primary completionEst.
Apr 30, 2027
CompletionEst.
Aug 31, 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04924322
Lead sponsor
Yale University
Collaborators
Children's Hospital Colorado, Children's Hospital of Philadelphia, BJC HealthCare, Medical College of Wisconsin, Children's of Alabama, Golisano Children's Hospital, Maria Fareri Children's Hospital, Nationwide Children's Hospital, New York Presbyterian Hospital, Penn State University, University of Iowa, Johns Hopkins All Children's Hospital, University of Oklahoma, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Children's Hospital of Illinois at Peoria, Hassenfeld Children's Hospital
Responsible party
E. Vincent S. Faustino (Professor of Pediatrics (Critical Care), Yale University) — Principal investigator
First posted
Jun 11, 2021
Start date
May 11, 2022
Primary completion
Apr 30, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

E. Vincent Faustino, MD, MHS
Contact
vince.faustino@yale.edu
203-785-4651
Tara McPartland, MSW, MPH
Contact
tara.mcpartland@yale.edu
203-737-7173
E. Vincent Faustino, MD, MHS
principal investigator · Associate Professor of Pediatrics, Yale School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enoxaparin

Start the discussion